OssDsign Partners with Red One Medical

OssDsign, a global provider of reconstructive implant solutions, has entered into an agreement with Red One Medical, a private sector scout of medical innovation for the U.S. Department of Veterans Affairs (VA) and Department of Defense (DoD). Through the Distribution and Pricing Agreement (DAPA), American veterans and warfighters will have access to OssDsign’s products for treating patients who have suffered from cranial or spinal bone defects.
 
“We’re proud to have entered into a partnership with Red One Medical, one of the most respected medical technology private sector representatives to the U.S. government,” said Morten Henneveld, CEO, OssDsign.”Red One Medical and the VA only accept the very best, and we see the recognition from our collaborator as a clear acknowledgement of the high quality of our product portfolio. We’re honored to have the opportunity to provide treatment solutions for America’s veterans and military staff.” 
 
The Veterans Health Administration (VHA) is the largest integrated health care system in the United States, with nearly 1,300 healthcare facilities serving 9 million veterans across the nation. Accessing this significant federal marketplace via Red One Medical, which is a Service Disabled Veteran Owned Business (SDVOSB), marks an important commercial step forward for OssDsign.  
 
OssDsign’s  product portfolio consists of implant products in two areas: patient-specific implants for cranial surgeries and a synthetic bone graft for spinal fusion surgeries. Within cranial surgeries, OssDsign Cranial PSI is designed using state-of-the-art technology in material science and advanced 3D printing. Based on a biocompatible calcium phosphate composition, OssDsign Cranial PSI provides an innovative solution for various needs associated with cranial reconstruction. Today, many cranial implant technologies are associated with high rates of costly complications and patient suffering. Multiple studies report infection rates above 10 percent. In contrast, post-market  surveillance of  OssDsign’s Cranial PSI implants, which have been used in more than 1,000 cranioplasties so far, shows an exceptional performance with an observed infection rate of only 2 percent, leading to implant removal at a median follow up time of 21 months. 
 
For spinal fusion surgeries, OssDsign Catalyst is a nanosynthetic bone graft that stimulates the formation of healthy bone tissue. Data from a recently published pre-clinical study show that OssDsign Catalyst induced rapid and reliable bone formation and that successful fusion was achieved in 100 percent of the studied subjects at 26 weeks, compared to 60 percent in the group where a comparable market-cleared device was used.
 
“We’re always on the lookout for advanced medical products that can improve and transform the lives of America’s veterans and military members,” said Red One Medical’s CEO Charles Pollak. “When it comes to cranial implants, Sweden-based OssDsign is top-of-the-line, and its unique design may help reduce complications from these critical surgeries. We are also very encouraged by the data shown for OssDsign Catalyst and see the potential to improve clinical outcome from spinal fusion surgeries.” 
 
OssDsign’s vision is to provide regenerative solutions to all patients with cranial or spinal bone defects, so they can be restored and healed as naturally as possible. Driven by a commitment to give patients back the lives they deserve, OssDsign collaborates with surgeons to engineer better healing by integrating biomaterials with clinical design. Headquartered in Sweden, OssDsign supplies hospitals worldwide with implants for use in cranial reconstructions and other orthopaedic surgery applications.
 
Red One Medical identifies and delivers advanced medical and pharmaceutical technologies that transform care for America’s veterans and military service members. Located in Savannah, Ga., Red One Medical donates a portion of profits to charities that support veterans, military families and their communities.